SNDX - Syndax Pharmaceuticals, Inc.
NEXT EARNINGS:
Mar 2, 2026
(in 5 days)
EPS Est: $-0.64
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$39.00
DETAILS
HIGH:
$44.00
LOW:
$35.00
MEDIAN:
$38.00
CONSENSUS:
$39.00
UPSIDE:
89.97%
Market Cap:
1.78B
Volume:
633,047
Avg Volume:
1,459,950
52 Week Range:
8.58-22.73
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.44
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
270
IPO Date:
2016-03-02
EPS (TTM):
-3.73
P/E Ratio:
-3.55
Revenue (TTM):
23.68M
Total Assets:
724.82M
Total Debt:
345.74M
Cash & Equiv:
154.08M
Rev Growth (5Y):
73.2%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-50.5%
Debt/Equity:
1.20
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-03 | $-0.70 | $-0.74 | +5.4% | $45.9M | $63.3M | -27.6% |
| 2025-08-04 | $-0.83 | $-1.00 | +17.0% | $38.0M | $45.7M | -16.9% |
| 2025-05-05 | $-0.98 | $-1.04 | +5.8% | $20.0M | $18.5M | +8.1% |
| 2025-03-03 | $-1.10 | $-1.08 | -1.9% | $7.7M | $12.8M | -39.9% |
| 2024-11-05 | $-0.98 | $-1.13 | +13.3% | $12.5M | $115.2M | -89.2% |
| 2024-08-01 | $-0.80 | $-0.91 | +12.1% | $3.5M | — | — |
| 2024-05-08 | $-0.85 | $-0.96 | +11.5% | — | — | — |
| 2024-02-27 | $-1.00 | $-0.99 | -1.0% | $536000 | — | — |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 23.68M | 0 | 0 | 139.71M | 1.52M | 1.52M | 1.52M | 2.11M | 1.22M | 627,000 | 0 | 0 |
| Net Income | (318.76M) | (209.36M) | (149.34M) | 24.93M | (73.07M) | (55.95M) | (73.96M) | (60.80M) | (44.47M) | (24.12M) | (19.83M) | (14.17M) |
| EPS | -3.73 | -2.98 | -2.46 | 0.48 | -1.77 | -1.84 | -2.92 | -2.90 | -3.04 | -4.31 | -2.07 | -1.77 |
| Total Assets | 724.82M | 612.88M | 497.24M | 449.66M | 300.61M | 63.52M | 83.94M | 137.19M | 109.01M | 89.90M | 12.82M | 17.06M |
| Total Debt | 345.74M | 1.64M | 1.16M | 20.97M | 20.54M | 897,000 | 0 | 0 | 0 | 0 | 13.88M | 0 |
| Cash & Equivalents | 154.08M | 295.39M | 74.36M | 221.97M | 115.24M | 24.61M | 33.77M | 35.17M | 23.84M | 23.18M | 10.01M | 10.10M |
| Operating Cash Flow | (274.90M) | (160.60M) | (133.68M) | 29.13M | (71.26M) | (50.61M) | (68.53M) | (47.37M) | (35.16M) | (2.43M) | (14.39M) | (7.29M) |
| Free Cash Flow | (274.90M) | (160.60M) | (133.90M) | 29.00M | (71.26M) | (50.61M) | (68.72M) | (47.45M) | (35.42M) | (2.48M) | (14.40M) | (7.33M) |
| FCF per Share | -3.21 | -2.28 | -2.20 | 0.56 | -1.73 | -1.66 | -2.71 | -2.26 | -2.42 | -0.44 | -1.50 | -0.92 |
| Book Value | 288.12M | 554.20M | 467.45M | 408.37M | 252.19M | 31.60M | 53.05M | 104.32M | 84.14M | 66.70M | (5.72M) | 11.85M |
| Cash & ST Investments | 582.91M | 577.58M | 484.40M | 446.83M | 293.06M | 59.77M | 80.91M | 133.22M | 105.33M | 87.29M | 12.21M | 14.26M |
| ROC Equity | -1.11 | -0.38 | -0.32 | 0.06 | -0.29 | -1.77 | -1.39 | -0.58 | -0.53 | -0.36 | N/A | -1.20 |